CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ventyx Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ventyx Biosciences Inc
12790 El Camino Real, Suite 200
Phone: (858) 945-2393p:858 945-2393 SAN DIEGO, CA  92130  United States Ticker: VTYXVTYX
Business Summary
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairperson of the Board SheilaGujrathi 53 5/1/2021 5/1/2021
President, Chief Executive Officer, Founder, Director RajuMohan 67 11/22/2023 11/1/2018
Interim Principal Financial Officer, Interim Principal Accounting Officer Roy M.Gonzales 49 8/30/2024 8/30/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Oppilan Pharma, Ltd.
VENTYX BIOSCIENCES INC
VTYX
Zomagen Biosciences Belgium BV
Zomagen Biosciences Ltd.

General Information
Number of Employees: 79 (As of 12/31/2024)
Outstanding Shares: 71,161,201 (As of 4/10/2025)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 832996852
Fax Number: (302) 655-5049
Email Address: info@ventyxbio.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, May 8, 2025